Speaker | Author | Executive Director, @IQVIA_Institute | Sharing Human Data Science | Providing objective insights for the advancement of human health globally
Proud to share the latest publication from the IQVIA Institute: our annual report on Global Trends in R&D. Download for details on the current landscape.
Biopharma R&D is regaining momentum. In 2024, funding reached $102B, emerging biopharma companies led 63% of clinical trial starts, and novel modalities drove 35% of oncology trials.
Download the report: https://t.co/fCh1qcBbP4.
Our latest examines state-level research on pharmacist vaccination authority policies and analyzes state-level adult vaccination rates for the RSV, pneumococcal, and shingles vaccines. Read more.
Empowering pharmacists boosts adult vaccination rates. A new IQVIA Institute report reveals that states granting pharmacists greater vaccine administration authority see improved immunization uptake: https://t.co/KIwHVKZsAl. #Vaccines#PublicHealth
A new report from @IQVIA_Institute about the Proliferation of Innovation Over Time examines how drug innovation advances post-FDA approval, highlighting impacts of policies like the Inflation Reduction Act. Download now: https://t.co/90gUE8evRh.
Timely access to radioligand therapy (RLT) depends on efficient referral pathways.
Our new report examines challenges in RLT patient referrals across Germany, Italy, France and China, offering solutions to reduce delays.
Read now: https://t.co/GZYbDITiei.
Biologic medicines make up nearly half of U.S. medicine spending, yet biosimilar competition isnβt guaranteed. With 118 biologics set to lose patent protection by 2034, key barriers could limit development. Explore solutions: https://t.co/4VyfhWeL9a. #Biosimilars
How can the life sciences sector measure progress in 2025?
Our latest research brief identifies key indicators shaping trust, innovation, & access. Learn about driving meaningful advancements for patients & stakeholders: https://t.co/Afr3AeabhO. #LifeSciences
Innovation in #DigitalHealth remains strong, despite recent market challenges. Our latest report explores trends in diagnostics, digital therapeutics, and AI-driven solutions reshaping care for patients and providers. https://t.co/dFL7iXT48I
More than 500 novel drugs were approved in the U.S., EU, and Japan from 2014-2022, but access varies widely. The latest IQVIA Institute report examines what drives these disparities and how to improve availability: https://t.co/7ZGBI3eaCx.
Latest from IQVIA Institute: Research brief looks at data and context on net drug spending for the first set of drugs selected for negotiations by the U.S. Centers for Medicare & Medicaid Services - including impact on patient out-of-pocket costs.
Just released: IQVIA Institute's latest report on CMS Prescription Drug Negotiations and the impact of the Inflation Reduction Act (IRA) on Medicare drug prices. Full insights here: https://t.co/ZioFDdqFf4 #Medicare#PharmaSpending
Introducing IQVIA Institute's report on Long-term Market Sustainability for Infused Biosimilars in the U.S. Explore insights into the challenges and opportunities shaping the future of biosimilars. π₯π
π https://t.co/QqYSLTyElB #Biosimilars#PharmaSpending
π IQVIA Institute's latest report on the Global Use of Medicines 2024 is now available. View the trends and forecasts shaping the future of healthcare with an outlook to 2028: https://t.co/c1f11xgtN1 #PharmaInsights#GlobalHealth
The latest IQVIA Institute report on Radioligand Therapy (RLT) reveals its clinical benefits in treating various cancers. Despite rapid scientific progress, healthcare system readiness lags behind. Full report: https://t.co/iYfHyfCvKI #CancerResearch#HealthcareInnovation
Read IQVIA Institute's research brief on how urban policies play a pivotal role in ensuring equitable access to adult vaccines. ποΈπ Dive into the data from 5 diverse cities - Brussels, Manchester, Bangkok, Chicago, and New York: https://t.co/YdGyYytl91 #GlobalHealth#Vaccines
π¨A new report from the IQVIA Institute assesses the drug shortages reported by @US_FDA in conjunction with sales and volume data of these medicines in the U.S. market. Download the report to learn the causes and impacts of these shortages: https://t.co/zBU5Vo2Ixe #drugshortages
π¬Just in: The latest IQVIA Institute report dives deep into the world of biosimilars in Europe. The findings explore the ins and outs of biosimilar development, revealing areas with potential competition and those that need a boost:Β https://t.co/XG7hNc8Tvi. #Biosimilars
IQVIA Instituteβs latest report on Supporting Patients through Research Collaboration is live. Learn how life sciences companies can forge better and more productive collaborations with patient organizations: https://t.co/r1uo0wSd0Z.
#PatientAdvocacy#PatientOutcomes
IQVIA Institute's Global Oncology Trends 2023 report examines the current state of research and development in oncology. Read the full report for more trends in the use of novel mechanisms in specific cancer types: https://t.co/xnGNaH36k2
#Oncology#Cancer Research
Explore our new report on The Use of Medicines in the U.S. 2023. Learn more about usage and spending trends within the U.S. healthcare system and read about our outlook toward 2027. https://t.co/kGYf06EOsp #Pharma
New Report: Assessing the Impact of Illegal Online Pharmacies in the U.S.: Sales, Volume and Adverse Events. Learn about the nature and use of illegal online pharmacies in recent years: https://t.co/sufWJSwqBF #SafeMedicines#TranslucentDatalab